Apogee Therapeutics (NASDAQ:APGE) Reaches New 52-Week High - Here's Why

Key Points

• Shares hit a new 52‑week high (intraday $85.04) after positive Phase II Part A 52‑week results for zumilokibart and bullish buy‑side commentary ahead of upcoming Part B and potential Phase 3 catalysts.
• Apogee priced an underwritten public offering of 5,000,000 shares at $70 per share (~$350M gross) with a 30‑day option for up to 750,000 additional shares, which raises cash but is dilutive and was set below the current market.
• Analysts remain broadly positive — consensus rating Moderate Buy with a $110.43 target — even as insiders have sold roughly 1.84M shares over the past 90 days (insiders still own 42.77%).

Shares of Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $85.04 and last traded at $78.53, with a volume of 3533056 shares changing hands. The stock had previously closed at $73.00.

More Apogee Therapeutics News

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Positive 52‑week Phase II Part A results for zumilokibart showing sustained, durable responses and attractive infrequent dosing — data cited as boosting the drug’s commercial promise and near‑term clinical catalysts (Part B 16‑week induction data in Q2; potential Phase 3 in H2 2026). Zacks: APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy
• Positive Sentiment: Investor enthusiasm reinforced by buy‑side commentary and bullish coverage calling APGE a “Strong Buy” ahead of upcoming readouts and potential Phase 3 start. Seeking Alpha highlights the program’s extended‑half‑life profile and upcoming catalysts. Seeking Alpha: Strong Buy
• Positive Sentiment: Several firms raised price targets and maintained buy ratings (Citigroup, Canaccord, Guggenheim), increasing upside estimates and supporting near‑term investor optimism. Benzinga: Analyst Coverage TickerReport: Guggenheim Raise
• Neutral Sentiment: Reported short‑interest data appears anomalous (entries showing 0 shares and NaN changes across multiple reports), so there’s no clear short‑pressure signal to explain price moves; treat the short‑interest items as unreliable until clarified.
• Negative Sentiment: Apogee priced an underwritten public offering of 5,000,000 shares at $70.00 (aggregate gross proceeds ~$350M) with a 30‑day option for up to 750,000 additional shares — this raises cash and extends runway but is dilutive and was priced below the current market, which can cap near‑term upside. Closing expected March 26, subject to conditions. GlobeNewswire: Offering Announcement MSN: Offering Coverage

Analyst Ratings Changes

Several research firms have recently issued reports on APGE. Stephens initiated coverage on Apogee Therapeutics in a research report on Tuesday, December 16th. They issued an "overweight" rating and a $95.00 price target on the stock. UBS Group upgraded Apogee Therapeutics to a "strong-buy" rating in a report on Wednesday, January 7th. Royal Bank Of Canada decreased their target price on Apogee Therapeutics from $83.00 to $82.00 and set a "sector perform" rating for the company in a research report on Monday, March 2nd. Jefferies Financial Group reiterated a "buy" rating and issued a $95.00 price target on shares of Apogee Therapeutics in a research report on Monday, February 2nd. Finally, Wolfe Research assumed coverage on shares of Apogee Therapeutics in a report on Wednesday, January 7th. They set a "peer perform" rating for the company. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $110.43.

Apogee Therapeutics Price Performance

The company has a market cap of $5.46 billion, a price-to-earnings ratio of -18.61 and a beta of 1.39. The stock has a 50-day moving average price of $71.09 and a 200 day moving average price of $64.05.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.02. Sell-side analysts expect that Apogee Therapeutics Inc. will post -3.09 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Michael Thomas Henderson sold 20,000 shares of the business's stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $74.78, for a total value of $1,495,600.00. Following the sale, the chief executive officer directly owned 1,152,987 shares of the company's stock, valued at approximately $86,220,367.86. The trade was a 1.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Carl Dambkowski sold 5,500 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $71.06, for a total value of $390,830.00. Following the transaction, the insider owned 209,773 shares of the company's stock, valued at approximately $14,906,469.38. This trade represents a 2.55% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,839,700 shares of company stock worth $140,118,083 over the last ninety days. Company insiders own 42.77% of the company's stock.

Hedge Funds Weigh In On Apogee Therapeutics

A number of large investors have recently bought and sold shares of APGE. Rockefeller Capital Management L.P. acquired a new stake in shares of Apogee Therapeutics in the fourth quarter valued at approximately $25,000. ANTIPODES PARTNERS Ltd grew its position in Apogee Therapeutics by 41.2% in the third quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company's stock valued at $33,000 after purchasing an additional 246 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Apogee Therapeutics in the 4th quarter valued at $37,000. Quantbot Technologies LP bought a new stake in Apogee Therapeutics during the 3rd quarter worth about $96,000. Finally, Seven Fleet Capital Management LP acquired a new position in shares of Apogee Therapeutics during the 4th quarter worth about $136,000. Institutional investors and hedge funds own 79.04% of the company's stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.